about
P1889
Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromesLow dose cytarabine monotherapy for acute myeloid leukaemiaIdiotype vaccination for Non-Hodgkin lymphomaIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersHypomethylating agents for patients with myelodysplastic syndromeAntibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationHypomethylating agents for adult patients with acute myeloid leukaemiaAdditional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaPositron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphomaProphylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapyAerobic physical exercise for adult patients with haematological malignanciesEffects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))Mindfulness-based stress reduction for women diagnosed with breast cancerYoga in addition to standard care for patients with haematological malignanciesMeditation for adult patients with haematological malignanciesFirst-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesThrombopoietin mimetics for patients with myelodysplastic syndromesPurine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemiaYoga for haematological malignanciesAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationHigh-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaErythropoietin or darbepoetin for patients with cancerAdditional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patientsPositron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patientsRole of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adultsAntiviral agents for prophylaxis of herpesviridae infections in patients with haematological malignanciesHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaLow dose cytarabine monotherapy for myelodysplastic syndromesGranulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromesComparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphomaIdiotype vaccination for Non-Hodgkin lymphomaQ24235340Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationThe role of physical exercise for adult patients with haematological malignanciesAutologous stem cell transplantation vs chemotherapy in adult acute lymphocytic leukaemiaHigh-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patientsThe role of additional radiotherapy for primary central nervous system lymphoma (PCNSL)Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T cell lymphoma
P50
Q24186133-EF10CBFA-F3E7-4E77-AEEC-346DEDD3806BQ24186270-0E69F3CA-2ABE-4281-B235-5A3E3C466B20Q24186272-9266F4E4-22B2-45F3-99B3-948F6A7BF1E9Q24186274-27BB1318-5D17-400E-BF40-7F17471D82DEQ24186276-2EC5FD6F-40A3-4600-B5B6-84D49A279F2FQ24186282-65B4D7BE-B546-4361-B652-1B029270FFE9Q24186284-509532DA-9C60-40E7-964D-5E6F5D824AE0Q24186469-DA1FD209-05FA-4AC0-B7DC-3EDCC30D561EQ24186668-B82D8AAD-4631-4427-8392-B0B61223E894Q24187043-C7407CBE-4BD3-4E94-9CE1-DB4CC4C54EF7Q24188047-8E5BB37C-865D-4F1C-AE20-CD2C0EE37D14Q24188096-1127E9FD-9075-447D-825D-BC80E14D2ACCQ24188348-E5D673CE-E57A-4A79-99BE-E802976534ADQ24194030-7C62F0BB-9821-4CB5-A45D-2D9A9FC231D5Q24194337-CFFF039C-3D5B-441F-8874-8A86B62BCE9FQ24197999-BC2E2B2F-12E5-4E4F-A7C0-4FC9CCCF813AQ24198060-69545BD5-7516-49C9-8EBB-28070549D3CFQ24198941-9D54AB8D-4F0F-4CC1-8D7D-386BEDF385BBQ24198951-CF21A006-8F40-4872-8D83-6742E05C4123Q24200225-2E35B06E-EEAF-4AD5-8639-F4F80506F4D7Q24201885-D9582D50-DA26-47F7-8A11-B466F770424CQ24202335-0C62EB60-129B-43D3-8903-9AF83E5FB806Q24202384-20D4B984-5A76-40A1-B3B6-DFFD959840E6Q24202622-52CABBBC-206D-4C54-AA1D-73EFE57B93DAQ24202784-4EE351D3-A6D0-4626-AC62-F460D400D1B4Q24203878-4FD75A8C-A825-4866-8FE4-EF7C2098AF9EQ24234350-97EDA524-E0BB-46C5-A2F9-E2D519922E2FQ24234645-64A0DD11-9B1E-4FC3-AFC1-CAD341FCC4D1Q24234680-57F88BAD-1C6E-4260-9389-497098582FE5Q24234789-4194EC46-9D29-4D24-98C5-B1454C347EA5Q24234828-B71A7144-B841-49B7-B6FE-B276B31AB8A5Q24234975-99E0CAEC-BAAE-4EAB-830A-2D28FE85E6D5Q24235281-7D78E006-9A40-4B4B-AAD0-BD18FE1C9682Q24235340-0CBCF073-EEAD-42CA-9A0D-A154BE50B98CQ24235345-FA4D2C81-8004-4691-8275-74D92246F6C6Q24235352-F44A3364-15DF-459C-B53C-D234EFB1B8B9Q24235485-B1AFB70C-6385-4180-A10D-07552135740FQ24235563-3B7CC4F4-0F1C-4763-B203-0F1D1D9CA2D5Q24236186-7106DDA7-7DAE-4D84-B0DD-E99FF7F231FEQ24236260-7292FD84-6D6C-4044-A8D8-33CF0FC13F57
P50
description
Arzt
@de
internist
@nl
name
Andreas Engert
@ast
Andreas Engert
@br
Andreas Engert
@co
Andreas Engert
@da
Andreas Engert
@de
Andreas Engert
@en
Andreas Engert
@es
Andreas Engert
@fr
Andreas Engert
@id
Andreas Engert
@it
type
label
Andreas Engert
@ast
Andreas Engert
@br
Andreas Engert
@co
Andreas Engert
@da
Andreas Engert
@de
Andreas Engert
@en
Andreas Engert
@es
Andreas Engert
@fr
Andreas Engert
@id
Andreas Engert
@it
prefLabel
Andreas Engert
@ast
Andreas Engert
@br
Andreas Engert
@co
Andreas Engert
@da
Andreas Engert
@de
Andreas Engert
@en
Andreas Engert
@es
Andreas Engert
@fr
Andreas Engert
@id
Andreas Engert
@it
P214
P227
P244
P106
P108
P1889
P21
P214
P227
P244
nb2007025482
P31
P735
P7859
lccn-nb2007025482